Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study

J Cuzick, GP Swanson, G Fisher, AR Brothman… - The lancet …, 2011 - thelancet.com
Background Optimum management of clinically localised prostate cancer presents unique
challenges because of the highly variable and often indolent natural history of the disease …

Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort

J Cuzick, S Stone, G Fisher, ZH Yang, BV North… - British journal of …, 2015 - nature.com
Background: The natural history of prostate cancer is highly variable and difficult to predict
accurately. Better markers are needed to guide management and avoid unnecessary …

Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort

J Cuzick, DM Berney, G Fisher, D Mesher… - British journal of …, 2012 - nature.com
Background: The natural history of prostate cancer is highly variable and it is difficult to
predict. We showed previously that a cell cycle progression (CCP) score was a robust …

Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort

MR Cooperberg, JP Simko, JE Cowan… - Journal of Clinical …, 2013 - escholarship.org
PurposeWe aimed to validate a previously described genetic risk score, denoted the cell-
cycle progression (CCP) score, in predicting contemporary radical prostatectomy (RP) …

Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study

E Lalonde, AS Ishkanian, J Sykes, M Fraser… - The lancet …, 2014 - thelancet.com
Background Clinical prognostic groupings for localised prostate cancers are imprecise, with
30–50% of patients recurring after image-guided radiotherapy or radical prostatectomy. We …

Analytic and clinical validation of a prostate cancer–enhanced messenger RNA detection assay in whole blood as a prognostic biomarker for survival

DC Danila, A Anand, N Schultz, G Heller, M Wan… - European urology, 2014 - Elsevier
Background Biomarkers based on detecting prostate cancer (PCa)-specific transcripts in
blood are associated with inferior outcomes, but their validation in a clinical context is …

Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy

SJ Freedland, L Gerber, J Reid, W Welbourn… - International Journal of …, 2013 - Elsevier
Purpose To evaluate the prognostic utility of the cell cycle progression (CCP) score, a RNA
signature based on the average expression level of 31 CCP genes, for predicting …

RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1

JR Prensner, S Zhao, N Erho, M Schipper… - The lancet …, 2014 - thelancet.com
Background Improved clinical predictors for disease progression are needed for localised
prostate cancer, since only a subset of patients develop recurrent or refractory disease after …

Molecular sampling of prostate cancer: a dilemma for predicting disease progression

A Sboner, F Demichelis, S Calza, Y Pawitan… - BMC medical …, 2010 - Springer
Background Current prostate cancer prognostic models are based on pre-treatment prostate
specific antigen (PSA) levels, biopsy Gleason score, and clinical staging but in practice are …

Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study

D Olmos, D Brewer, J Clark, DC Danila… - The lancet …, 2012 - thelancet.com
Background Biomarkers are urgently needed to dissect the heterogeneity of prostate cancer
between patients to improve treatment and accelerate drug development. We analysed …